Regulatory approval
Published by the Health Canada. Approved
IRESSA (gefitinib) is indicated for the first line treatment of patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the EGFR-TK
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | EGFR Exon 19 (Deletion) | Non-Small Cell Lung Cancer | Gefitinib | |
| HC (1) | EGFR p.L858R | Non-Small Cell Lung Cancer | Gefitinib | |
| HC (1) | EGFR TKD activating variants | Non-Small Cell Lung Cancer | Gefitinib |